PH12016501310B1 - Pharmaceutical compositions comprising azd9291 - Google Patents
Pharmaceutical compositions comprising azd9291Info
- Publication number
- PH12016501310B1 PH12016501310B1 PH1/2016/501310A PH12016501310A PH12016501310B1 PH 12016501310 B1 PH12016501310 B1 PH 12016501310B1 PH 12016501310 A PH12016501310 A PH 12016501310A PH 12016501310 B1 PH12016501310 B1 PH 12016501310B1
- Authority
- PH
- Philippines
- Prior art keywords
- azd9291
- pharmaceutical compositions
- pharmaceutical
- compositions
- enamide
- Prior art date
Links
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 229960003278 osimertinib Drugs 0.000 title abstract 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008024 pharmaceutical diluent Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000007916 tablet composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to pharmaceutical compositions suitable for oral administration, and more particularly to pharmaceutical compositions, including pharmaceutical tablet compositions, containing N-(2-{2-dimethylaminoethyl- methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop- 2-enamide ("AZD9291") or a pharmaceutically acceptable salt thereof, wherein such compositions comprise a certain amount of microcrystalline cellulose and at least one other pharmaceutical diluent.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1400034.3A GB201400034D0 (en) | 2014-01-02 | 2014-01-02 | Pharmaceutical Compositions comprising AZD9291 |
| PCT/GB2015/050001 WO2015101791A1 (en) | 2014-01-02 | 2015-01-02 | Pharmaceutical compositions comprising azd9291 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PH12016501310A1 PH12016501310A1 (en) | 2016-09-14 |
| PH12016501310B1 true PH12016501310B1 (en) | 2022-07-06 |
Family
ID=50191689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2016/501310A PH12016501310B1 (en) | 2014-01-02 | 2015-01-02 | Pharmaceutical compositions comprising azd9291 |
Country Status (37)
| Country | Link |
|---|---|
| US (6) | US10183020B2 (en) |
| EP (1) | EP3089741B1 (en) |
| JP (1) | JP6588915B2 (en) |
| KR (1) | KR102336378B1 (en) |
| CN (2) | CN105848647B (en) |
| AR (1) | AR098989A1 (en) |
| AU (1) | AU2015204218B2 (en) |
| CA (1) | CA2933403C (en) |
| CL (1) | CL2016001609A1 (en) |
| CR (1) | CR20160310A (en) |
| CY (1) | CY1124848T1 (en) |
| DK (1) | DK3089741T3 (en) |
| DO (1) | DOP2016000156A (en) |
| EA (1) | EA034243B9 (en) |
| ES (1) | ES2873226T3 (en) |
| GB (1) | GB201400034D0 (en) |
| GT (1) | GT201600142A (en) |
| HR (1) | HRP20210749T1 (en) |
| HU (1) | HUE054344T2 (en) |
| IL (1) | IL246186B (en) |
| LT (1) | LT3089741T (en) |
| MX (1) | MX367358B (en) |
| MY (1) | MY183536A (en) |
| NI (1) | NI201600098A (en) |
| NZ (1) | NZ721298A (en) |
| PE (1) | PE20161170A1 (en) |
| PH (1) | PH12016501310B1 (en) |
| PL (1) | PL3089741T3 (en) |
| PT (1) | PT3089741T (en) |
| RS (1) | RS61927B1 (en) |
| SG (1) | SG11201605339QA (en) |
| SI (1) | SI3089741T1 (en) |
| SM (1) | SMT202100330T1 (en) |
| TW (1) | TWI702953B (en) |
| UY (1) | UY35933A (en) |
| WO (1) | WO2015101791A1 (en) |
| ZA (1) | ZA201605300B (en) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201400034D0 (en) * | 2014-01-02 | 2014-02-19 | Astrazeneca Ab | Pharmaceutical Compositions comprising AZD9291 |
| NO2699580T3 (en) | 2014-01-24 | 2018-02-24 | ||
| SG11201809751XA (en) | 2016-05-26 | 2018-12-28 | Zeno Royalties & Milestones Llc | Egfr inhibitor compounds |
| CN108057036B (en) * | 2016-11-07 | 2023-06-13 | 正大天晴药业集团股份有限公司 | Solid pharmaceutical composition of EGFR inhibitor |
| CN107176954B (en) * | 2017-06-02 | 2019-01-11 | 无锡双良生物科技有限公司 | A kind of pharmaceutical salts and its crystal form, preparation method and application of EGFR inhibitor |
| CN110013468B (en) * | 2018-01-09 | 2022-02-18 | 北京福元医药股份有限公司 | AZD9291 deuterated derivative pharmaceutical preparation |
| WO2019138346A1 (en) * | 2018-01-10 | 2019-07-18 | Alembic Pharmaceuticals Limited | Pharmaceutical composition of osimertinib |
| TW201941773A (en) * | 2018-02-12 | 2019-11-01 | 瑞典商阿斯特捷利康公司 | Osimertinib for use in the treatment of non-small cell lung cancer |
| PL3758708T3 (en) * | 2018-03-01 | 2025-03-31 | Astrazeneca Ab | Pharmaceutical compositions comprising (2s)-{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide |
| WO2019178868A1 (en) | 2018-03-23 | 2019-09-26 | 无锡双良生物科技有限公司 | Pharmaceutical composition and preparation method therefor and uses thereof |
| EP3823627A4 (en) | 2018-07-17 | 2022-04-20 | Insmed Incorporated | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis |
| KR20200043618A (en) | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | Pharmaceutical composition for oral administration comprising an aminopyrimidine derivative or its salt |
| MX2021011810A (en) | 2019-03-29 | 2021-10-26 | Astrazeneca Ab | Osimertinib for use in the treatment of non-small cell lung cancer. |
| US20210161897A1 (en) | 2019-11-12 | 2021-06-03 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| AU2021211871A1 (en) | 2020-01-20 | 2022-09-08 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| US20210369709A1 (en) | 2020-05-27 | 2021-12-02 | Astrazeneca Ab | EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER |
| TW202304457A (en) * | 2021-03-22 | 2023-02-01 | 瑞典商阿斯特捷利康公司 | Formulation |
| IL315848A (en) | 2022-03-31 | 2024-11-01 | Astrazeneca Ab | Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer |
| CA3249080A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | CONDENSED BICYCLIC HETEROAROMATIC COMPOUNDS AND THEIR USE IN CANCER TREATMENT |
| US20240116926A1 (en) | 2022-04-28 | 2024-04-11 | Astrazeneca Ab | Heteroaromatic compounds |
| WO2023209090A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds and their application in the treatment of cancer |
| WO2023209088A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds and their use in the treatment of cancer |
| KR20250029133A (en) | 2022-06-27 | 2025-03-04 | 아스트라제네카 아베 | Combinations comprising epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| CN119654152A (en) | 2022-07-08 | 2025-03-18 | 阿斯利康(瑞典)有限公司 | Epidermal growth factor receptor tyrosine kinase inhibitors for use in combination with HGF-receptor inhibitors in the treatment of cancer |
| EP4646265A1 (en) | 2023-01-06 | 2025-11-12 | Insmed Incorporated | Novel, reversible dpp1 inhibitors and uses thereof |
| WO2025092926A1 (en) * | 2023-10-31 | 2025-05-08 | 浙江同源康医药股份有限公司 | Pharmaceutical composition of pyrimidine derivative |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL110376A (en) * | 1993-08-02 | 1998-08-16 | Bristol Myers Squibb Co | Pharmaceutical compositions containing ifetroban salts and methods for the preparation thereof |
| SE9802973D0 (en) * | 1998-09-03 | 1998-09-03 | Astra Ab | Immediate release tablet |
| WO2001076565A1 (en) * | 2000-04-12 | 2001-10-18 | Banyu Pharmaceutical Co., Ltd. | Compositions disintegrating in oral cavity and preparations disintegrating in oral cavity |
| US6881737B2 (en) | 2001-04-11 | 2005-04-19 | Amgen Inc. | Substituted triazinyl acrylamide derivatives and methods of use |
| KR101002374B1 (en) | 2002-02-26 | 2010-12-17 | 아스트라제네카 아베 | Pharmaceutical preparations of YRESA containing water-soluble cellulose derivatives |
| US20080102133A1 (en) * | 2004-10-05 | 2008-05-01 | Antje Brueck-Scheffler | Oral Pharmaceutical Preparation for Proton Pump Antagonists |
| ES2279715B1 (en) * | 2005-12-26 | 2008-06-01 | Laboratorios Lesvi, S.L. | ORAL FORMULATION OF OLANZAPINE. |
| TW200800181A (en) * | 2006-02-09 | 2008-01-01 | Sankyo Co | Pharmaceutical composition for anticancer |
| JP5576922B2 (en) * | 2006-04-20 | 2014-08-20 | 信越化学工業株式会社 | Solid formulation comprising an enteric solid dispersion |
| EP2170062A4 (en) * | 2007-07-12 | 2010-12-29 | Tragara Pharmaceuticals Inc | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, TUMORS AND TUMOR RELATED DISORDERS |
| WO2012139736A1 (en) | 2011-04-11 | 2012-10-18 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Pharmaceutical composition comprising bosentan |
| KR101317809B1 (en) | 2011-06-07 | 2013-10-16 | 한미약품 주식회사 | Pharmaceutical composition comprising amide derivative inhibiting the growth of cancer cell and non-metalic salt lubricant |
| PT3009431T (en) * | 2011-07-27 | 2017-12-26 | Astrazeneca Ab | 2-(2,4,5-substituted-anilino)pyrimidine derivatives as egfr modulators useful for treating cancer |
| ES2946549T3 (en) * | 2012-01-13 | 2023-07-20 | Xspray Pharma Ab Publ | Pharmaceutical composition of nilotinib |
| WO2013160916A1 (en) | 2012-04-25 | 2013-10-31 | Hetero Research Foundation | Sunitinib malate solid dispersion |
| GB201400034D0 (en) * | 2014-01-02 | 2014-02-19 | Astrazeneca Ab | Pharmaceutical Compositions comprising AZD9291 |
-
2014
- 2014-01-02 GB GBGB1400034.3A patent/GB201400034D0/en not_active Ceased
- 2014-12-29 AR ARP140104947A patent/AR098989A1/en not_active Application Discontinuation
- 2014-12-29 UY UY0001035933A patent/UY35933A/en not_active Application Discontinuation
- 2014-12-31 TW TW103146652A patent/TWI702953B/en active
-
2015
- 2015-01-02 MY MYPI2016702433A patent/MY183536A/en unknown
- 2015-01-02 CA CA2933403A patent/CA2933403C/en active Active
- 2015-01-02 PH PH1/2016/501310A patent/PH12016501310B1/en unknown
- 2015-01-02 US US15/109,170 patent/US10183020B2/en active Active
- 2015-01-02 AU AU2015204218A patent/AU2015204218B2/en active Active
- 2015-01-02 NZ NZ721298A patent/NZ721298A/en unknown
- 2015-01-02 HR HRP20210749TT patent/HRP20210749T1/en unknown
- 2015-01-02 EP EP15700082.9A patent/EP3089741B1/en active Active
- 2015-01-02 PE PE2016000943A patent/PE20161170A1/en unknown
- 2015-01-02 JP JP2016544368A patent/JP6588915B2/en active Active
- 2015-01-02 PT PT157000829T patent/PT3089741T/en unknown
- 2015-01-02 CN CN201580003266.4A patent/CN105848647B/en active Active
- 2015-01-02 RS RS20210698A patent/RS61927B1/en unknown
- 2015-01-02 CR CR20160310A patent/CR20160310A/en unknown
- 2015-01-02 MX MX2016008744A patent/MX367358B/en active IP Right Grant
- 2015-01-02 KR KR1020167020731A patent/KR102336378B1/en active Active
- 2015-01-02 SM SM20210330T patent/SMT202100330T1/en unknown
- 2015-01-02 LT LTEP15700082.9T patent/LT3089741T/en unknown
- 2015-01-02 CN CN202210324141.3A patent/CN114712362A/en active Pending
- 2015-01-02 DK DK15700082.9T patent/DK3089741T3/en active
- 2015-01-02 WO PCT/GB2015/050001 patent/WO2015101791A1/en not_active Ceased
- 2015-01-02 PL PL15700082T patent/PL3089741T3/en unknown
- 2015-01-02 HU HUE15700082A patent/HUE054344T2/en unknown
- 2015-01-02 ES ES15700082T patent/ES2873226T3/en active Active
- 2015-01-02 EA EA201691242A patent/EA034243B9/en not_active IP Right Cessation
- 2015-01-02 SI SI201531610T patent/SI3089741T1/en unknown
- 2015-01-02 SG SG11201605339QA patent/SG11201605339QA/en unknown
-
2016
- 2016-06-13 IL IL246186A patent/IL246186B/en active IP Right Grant
- 2016-06-22 DO DO2016000156A patent/DOP2016000156A/en unknown
- 2016-06-22 CL CL2016001609A patent/CL2016001609A1/en unknown
- 2016-06-29 GT GT201600142A patent/GT201600142A/en unknown
- 2016-07-01 NI NI201600098A patent/NI201600098A/en unknown
- 2016-08-01 ZA ZA2016/05300A patent/ZA201605300B/en unknown
-
2018
- 2018-11-20 US US16/196,185 patent/US20190111057A1/en not_active Abandoned
-
2020
- 2020-08-04 US US16/984,276 patent/US20200360378A1/en not_active Abandoned
-
2021
- 2021-06-08 CY CY20211100499T patent/CY1124848T1/en unknown
- 2021-09-17 US US17/478,117 patent/US20240189310A1/en not_active Abandoned
-
2022
- 2022-04-26 US US17/729,162 patent/US20220395502A1/en not_active Abandoned
-
2024
- 2024-09-26 US US18/897,609 patent/US20250017930A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY183536A (en) | Pharmaceutical compositions comprising azd9291 | |
| JOP20200122A1 (en) | Compounds useful for inhibiting cdk7 | |
| MX369818B (en) | Selective pyy compounds and uses thereof. | |
| PH12013502277A1 (en) | Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4 methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids | |
| GEP20186892B (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
| GEP20196949B (en) | 2-amino-6-(difluoromethyl)-5, 5-difluoro-6-phenyl-3, 4, 5, 6-tetra- hydropyridines as bace1 inhibitors | |
| SA519410865B1 (en) | Coumarin-like Cyclic Compound as MEK Inhibitor and Use Thereof | |
| MX394588B (en) | PHARMACEUTICAL COMPOSITION. | |
| TN2016000489A1 (en) | Carboxamide derivatives. | |
| EA201890534A1 (en) | NEW ANNELED PHENOXYCETAMIDES | |
| TN2016000491A1 (en) | Carboxamide derivatives. | |
| PH12017501444A1 (en) | (2r,4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | |
| WO2016006974A3 (en) | Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof | |
| WO2016006975A3 (en) | Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof | |
| AU2015280874A1 (en) | Novel heterocyclic compound | |
| EA201991286A1 (en) | A SOLID PHARMACEUTICAL COMPOSITION FOR ORAL USE CONTAINING TENOFOVIR AND EMTRITSITABIN | |
| EA202090913A1 (en) | COMPOSITION OF MODIFIED RELEASE TABLETS CONTAINING MIRABEGRON | |
| MY193080A (en) | Crystalline forms | |
| PH12017501832A1 (en) | Stabilized pharmaceutical composition | |
| PH12016502527B1 (en) | Stabilized desmopressin | |
| PH12018500946A1 (en) | Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof | |
| TR201721065A2 (en) | Lyophilized pharmaceutical formulations comprising dexmedetomidine | |
| TN2013000440A1 (en) | Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids | |
| GR1008804B (en) | Medical compositions containing hyaluronic acid or salts thereof, amino acids, vitamins, non-organic salts and other components |